


## PRODUCT REFERENCE GUIDE







Afrezza® is dispensed in convenient boxes to meet your patients' mealtime insulin needs.<sup>1</sup>

See below for a product reference guide, including all Afrezza NDC codes, their contents, and the maximum daily units per box.



COMBINATION BOX OPTIONS

SINGLE BOX OPTIONS

NDC	Afrezza Box Contents	1 Box (30-day supply)	2 Boxes (30-day supply)	3 Boxes (30-day supply)
 NDC 47918-0902-18	<b>Afrezza 4, 8 &amp; 12 Unit Cartridges</b> [60] 4-unit cartridges [60] 8-unit cartridges [60] 12-unit cartridges Total: 180 cartridges 1440 Afrezza Insulin Units	Total Insulin Units: 1440 Total Cartridges: 180 Max Total Daily Dose: 48 units	Total Insulin Units: 2880 Total Cartridges: 360 Max Total Daily Dose: 96 units	Total Insulin Units: 4320 Total Cartridges: 540 Max Total Daily Dose: 144 units
 NDC 47918-0880-18	<b>Afrezza 4 &amp; 8 Unit Cartridges</b> [90] 4-unit cartridges [90] 8-unit cartridges Total: 180 cartridges 1080 Afrezza Insulin Units	Total Insulin Units: 1080 Total Cartridges: 180 Max Total Daily Dose: 36 units	Total Insulin Units: 2160 Total Cartridges: 360 Max Total Daily Dose: 72 units	Total Insulin Units: 3240 Total Cartridges: 540 Max Total Daily Dose: 108 units
 NDC 47918-0898-18	<b>Afrezza 8 &amp; 12 Unit Cartridges</b> [90] 8-unit cartridges [90] 12-unit cartridges Total: 180 cartridges 1800 Afrezza Insulin Units	Total Insulin Units: 1800 Total Cartridges: 180 Max Total Daily Dose: 60 units	Total Insulin Units: 3600 Total Cartridges: 360 Max Total Daily Dose: 120 units	Total Insulin Units: 5400 Total Cartridges: 540 Max Total Daily Dose: 180 units
 NDC 47918-0874-90	<b>Afrezza 4-Unit Cartridges</b> [90] 4-unit cartridges Total: 90 cartridges 360 Afrezza Insulin Units	Total Insulin Units: 360 Total Cartridges: 90 Max Total Daily Dose: 12 units	Total Insulin Units: 720 Total Cartridges: 180 Max Total Daily Dose: 24 units	Total Insulin Units: 1080 Total Cartridges: 270 Max Total Daily Dose: 36 units
 NDC 47918-0878-90	<b>Afrezza 8-Unit Cartridges</b> [90] 8-unit cartridges Total: 90 cartridges 720 Afrezza Insulin Units	Total Insulin Units: 720 Total Cartridges: 90 Max Total Daily Dose: 24 units	Total Insulin Units: 1440 Total Cartridges: 180 Max Total Daily Dose: 48 units	Total Insulin Units: 2160 Total Cartridges: 270 Max Total Daily Dose: 72 units
 NDC 47918-0891-90	<b>Afrezza 12-Unit Cartridges</b> [90] 12-unit cartridges Total: 90 cartridges 1080 Afrezza Insulin Units	Total Insulin Units: 1080 Total Cartridges: 90 Max Total Daily Dose: 36 units	Total Insulin Units: 2160 Total Cartridges: 180 Max Total Daily Dose: 72 units	Total Insulin Units: 3240 Total Cartridges: 270 Max Total Daily Dose: 108 units

<sup>1</sup>. Afrezza (insulin human) Inhalation Powder Prescribing Information. MannKind Corporation.

#### Indications and Usage:

Afrezza® (insulin human) Inhalation Powder is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

#### Limitations of Use:

Patients with type 1 diabetes must use with a long-acting insulin, not recommended for the treatment of diabetic ketoacidosis, not recommended in patients who smoke.

#### Important Safety Information

**WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE**

- Acute bronchospasm has been observed in patients with asthma and COPD using AFREZZA.
- AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD.
- Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV<sub>1</sub>) to identify potential lung disease in all patients.

#### Contraindications

AFREZZA is contraindicated: during episodes of hypoglycemia, in patients with chronic lung disease (such as asthma or chronic obstructive pulmonary disease [COPD]) because of the risk of acute bronchospasm, and in patients with hypersensitivity to regular human insulin or any of the AFREZZA excipients.

#### Warnings and Precautions

**Acute Bronchospasm:** Acute bronchospasm has been observed following AFREZZA dosing in patients with asthma and COPD. Prior to initiating therapy, evaluate patients with a medical history, physical examination and spirometry (FEV<sub>1</sub>) to identify potential underlying lung disease. Do not use in patients with COPD.

**Change in Insulin Regimen:** Monitor blood glucose in all patients treated with insulin. Modify insulin regimen and dose cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

**Hypoglycemia:** Hypoglycemia is the most common adverse reaction of insulin therapy, including AFREZZA, and may be serious and life-threatening. Educate patients and caregivers on recognizing symptoms and mitigating the risks associated with hypoglycemia.

**Decline in Pulmonary Function:** AFREZZA has been shown to cause a decrease in lung function as measured by FEV<sub>1</sub>. In clinical trials lasting up to 2 years, AFREZZA treated patients experienced a small (40 mL) but greater FEV<sub>1</sub> decline than comparator treated patients. Assess pulmonary function with spirometry at baseline, after the initial 6 months of therapy and annually thereafter even in the absence of pulmonary symptoms. In patients who have a decline of  $\geq 20\%$  in FEV<sub>1</sub> from baseline, consider discontinuing AFREZZA. Consider more frequent lung function assessment in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough. If symptoms persist, discontinue AFREZZA.

**Lung Cancer:** In clinical trials, 2 cases of lung cancer were reported in patients exposed to AFREZZA while no cases were reported for the comparators. Two additional cases of lung cancer (squamous cell and lung blastoma) were reported in non-smokers exposed to AFREZZA after the trial completion. These data are insufficient to determine whether AFREZZA has an effect on lung or respiratory tract tumors. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of AFREZZA outweigh the risks.

**Diabetic Ketoacidosis (DKA):** In clinical trials enrolling subjects with type 1 diabetes, diabetic ketoacidosis (DKA) was more common in subjects receiving AFREZZA (0.43%; n=13) than in subjects receiving comparators (0.14%; n=3). Increase the frequency of glucose monitoring and consider an alternate route of administration of insulin in patients at risk for DKA.

**Hypersensitivity Reactions:** Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue AFREZZA, monitor and treat if indicated.

**Hypokalemia:** All insulin products, including AFREZZA, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

**Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs):** Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of TZDs and insulin. Observe these patients for signs and symptoms of heart failure. If heart failure occurs, consider dose reduction or discontinuation of TZD.

#### Drug Interactions

Certain drugs may affect glucose metabolism, increasing the risk of hypoglycemia or decreasing the blood glucose lowering effect of AFREZZA. Dose adjustment and increased frequency of blood glucose monitoring may be required. Co-administration of beta-blockers, clonidine, guanethidine, and reserpine with AFREZZA may reduce the signs and symptoms of hypoglycemia. For full list, see Prescribing Information.

#### Adverse Reactions

The most common adverse reactions associated with AFREZZA include hypoglycemia, cough, and throat pain or irritation.

Please see [Full Prescribing Information](#), including **BOXED WARNING**, for AFREZZA on [www.afrezzahcp.com](http://www.afrezzahcp.com).